Harnessing molecular probes for imaging of human epidermal growth factor receptor (HER) family
N Li, S Chen, X Cai - Bioorganic & Medicinal Chemistry, 2024 - Elsevier
The human epidermal growth factor receptor (HER) family plays a critical role in the
development, migration, and invasion of various cancers. Currently, the FDA has approved …
development, migration, and invasion of various cancers. Currently, the FDA has approved …
[HTML][HTML] Diagnostic Accuracy of Immunohistochemistry for HER2-Positive Breast Cancer
S Thanasan, K Sukhakul, S Chitpakdee… - Asian Pacific journal …, 2023 - ncbi.nlm.nih.gov
Objective: Currently, human epidermal growth factor receptor 2 (HER2)-positive breast
cancer cells are diagnosed under the American Society of Clinical Oncology (ASCO) and …
cancer cells are diagnosed under the American Society of Clinical Oncology (ASCO) and …
Are There More HER2 FISH in the Sea? An Institution's Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 …
C Suydam, F Chibane, N Brown, M Schlafly… - Annals of surgical …, 2024 - Springer
Background Approximately 20% of breast cancers express HER2-positive receptors in the
USA. HER2 receptor immunohistochemistry (IHC) staining with equivocal (2+) results …
USA. HER2 receptor immunohistochemistry (IHC) staining with equivocal (2+) results …
Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP …
BR Nagarjun, B Parikh, MN Patel… - South Asian Journal …, 2022 - thieme-connect.com
Introduction Hormonal status and HER2 expression are valuable biomarkers and dictate the
management of the patients diagnosed with invasive breast cancer (IBC). It is crucial to …
management of the patients diagnosed with invasive breast cancer (IBC). It is crucial to …
[HTML][HTML] The concordance between IHC and ISH for HER-2 testing in breast cancer in Nakhon Pathom Hospital, Thailand, based on the ASCO/CAP 2018 guidelines: a …
T Thambamroong - ecancermedicalscience, 2022 - ncbi.nlm.nih.gov
Human epidermal growth factor receptor 2 (HER-2) is the prognostic and predictive
biomarker for breast cancer found in a quarter of all breast cancer cases. Precise testing of …
biomarker for breast cancer found in a quarter of all breast cancer cases. Precise testing of …
[HTML][HTML] Her2 expression can predict the survival of patients with salivary duct carcinoma
T Kawano, T Hirano, S Takakura, K Ito, M Urabe… - Clinical Immunology …, 2022 - Elsevier
Salivary duct carcinoma (SDC) is a high-grade malignant tumor that mainly develops in the
salivary glands, and SDC patients have a 5-year survival rate of less than 50%. Thirteen …
salivary glands, and SDC patients have a 5-year survival rate of less than 50%. Thirteen …